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Summary  
 
Cryptococcus neoformas infection of the central nervous system (CNS) continues to be 
an important cause of mortality and morbidity, and a major contributing factor is our 
incomplete knowledge of the pathogenesis of this disease. Here we provide the first direct 
evidence that C. neoformans exploits host cysteinyl leukotrienes (LTs), formed via LT 
biosynthetic pathways involving cytosolic phospholipase A2α (cPLA2α) and 5-
lipoxygenase (5-LO) and acting via cysteinyl leukotriene type 1 receptor (CysLT1), for 
penetration of the blood-brain barrier. Gene deletion of cPLA2α and 5-LO as well as 
pharmacological inhibition of cPLA2α, 5-LO and CysLT1 were effective in preventing C. 
neoformans penetration of the blood-brain barrier in vitro and in vivo. A CysLT1 
antagonist enhanced the efficacy of an anti-fungal agent in therapy of C. neoformans 
CNS infection in mice. These findings demonstrate that host cysteinyl LTs, dependent on 
the actions of cPLA2α and 5-LO, promote C. neoformans penetration of the blood-brain 
barrier and represent novel targets for elucidating the pathogenesis and therapeutic 
development of C. neoformans CNS infection.  
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Introduction 
 
 
 
C. neoformans is responsible for life-threatening CNS infection in immunocompromised 
patients, especially those infected with HIV-1 (Day et al., 2013； Eisenman et al., 2007; 
Hakim et al., 2000; Jarvis et al., 2013; Mitchell et al., 1995; Mwaba et al., 2001; Park et 
al., 2009; Perfect et al., 2002; Powderly et al., 1993; Saag et al., 2000; Warkentien et al., 
2010). One million cases of cryptococcal meningoencephalitis are estimated to occur 
globally per year, with >60% mortality within 3 months of infection (Day et al., 2013; 
Mwaba et al., 2001; Park et al., 2009). Even when treatment with amphotericin B and 
flucytosine is available, mortality ranges between 15-30% and is much higher (41-70%) 
in low-income countries where such antifungal regimens are not readily accessible (Day 
et al., 2013; Jarvis et al., 2013; Mwaba et al., 2001; Park et al., 2009; Saag et al., 2000). 
A recent study reported that cerebrospinal fluid (CSF) fungal burden predicts acute 
mortality in HIV-associated cryptococcal meningoencephalitis (Jarvis et al., 2013). These 
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findings illustrate the need for a novel strategy for decreasing fungal burden in improving 
outcomes in HIV-infected patients.  
 
C. neoformans CNS infection is a leading contributor to mortality in HIV-infected 
individuals with CD4+ counts <100 cells/µl, the threshold at risk for cryptococcal CNS 
infection, and blood cryptococcal antigen (CRAG) screen and early institution of 
preemptive antifungal therapy is shown to be efficacious in improving survival 
(Boulware et al., 2014; Jarvis et al., 2009; Meya et al., 2010).  A 6-month survival in 
asymptomatic CRAG+ persons with CD4 <100/µl, however, is approximately 75% with 
the currently recommended WHO therapy, fluconazole (Boulware et al., 2014; Jarvis et 
al., 2009; Meya et al., 2010). The timing of mortality, occurring several weeks later, 
suggests that better antifungal therapy may be able to improve outcomes. These findings 
indicate that new approaches are needed to investigate the pathogenesis, prevention and 
therapy of C. neoformans CNS infection. Development of such a strategy, however, has 
been hampered by our incomplete knowledge on how C. neoformans penetrates the 
blood-brain barrier (Kim, 2008), the essential step required for the development of CNS 
infection. 
 
C. neoformans is commonly acquired by inhalation.  Extrapulmonary dissemination to 
the bloodstream leads to infection of distant organs, resulting in meningoencephalitis 
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(Day et al., 2013; Eisenman et al., 2007; Hakim et al., 2000; Jarvis et al., 2013; Mitchell 
et al., 1995; Mwaba et al., 2001; Park et al., 2009; Perfect et al., 2002; Powderly et al., 
1993; Saag et al., 2000; Warkentien et al., 2010). Several lines of evidence from human 
cases and experimental animal models of C. neoformans meningoencephalitis indicate 
that C. neoformans penetration into the brain follows fungemia, and cerebral capillaries 
are the portal of entry into the brain (Chang et al., 2004; Charlier et al., 2005; Chretien et 
al., 2002; Lee et al., 1996; Neuville et al., 2002; Olszewski et al., 2004; Shi et al., 2010). 
Since the entry of C. neoformans into the brain occurred in the cerebral microvasculature, 
we developed an in vitro blood-brain barrier model with human brain microvascular 
endothelial cells (HBMEC) (Chang et al., 2004; Kim, 2008, Kim et al.; 2004; Maruvada 
et al., 2012; Rüffer et al., 2004; Stins et al., 1997) for investigating C. neoformans 
penetration of the blood-brain barrier.  
 
C. neoformans penetration into the brain has been shown to involve mainly transcellular 
and Trojan-horse penetrations of the blood-brain barrier and has been examined in animal 
models of intravenous, intranasal and intratracheal inoculations (Chang et al., 2004; 
Charlier et al., 2005; Chretien et al., 2002; Dromer et al., 2011; Kim, 2008; Neuville et 
al., 2002; Olszewski et al., 2004; Shi et al., 2010). Transcellular and Trojan-horse 
penetrations may not be mutually exclusive and can function in parallel in these animal 
models (Dromer et al., 2011). We showed that C. neoformans strains exhibit the ability to 
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traverse the HBMEC monolayer without affecting HBMEC integrity, and HBMEC 
traversal is correlated with C. neoformans penetration into the brain (Chang et al., 2004; 
Kim, 2008; Maruvada et al., 2012; Shi et al., 2010). The underlying mechanisms 
involved in C. neoformans penetration of the blood-brain barrier, however, remain 
incompletely understood.   
 
Previous studies have identified several cryptococcal and host factors contributing to 
penetration into the brain, which include a cryptococcal metalloprotease as well as cps1-
CD44 and plb1-Rac1 interactions (Vu et al, 2014; Chang et al, 2006; Jong et al, 2012; 
Maruvada et al, 2012). We identified the CysLT1 antagonist, montelukast from our 
chemical screen inhibiting C. neoformans traversal of HBMEC monolayer. CysLT1 has 
been previously shown to contribute to invasion of HBMEC monolayer and penetration 
into the brain by bacteria causing meningitis such as E. coli and group B Streptococcus  
(Zhu et al, 2010; Maruvada et al, 2012).  Here we elucidated the mechanisms by which 
cysteinyl leukotrienes are generated and contribute to C. neoformans penetration of the 
blood-brain barrier in vitro and in vivo. 
 
Results and Discussion 
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Since C. neoformans traversal of the HBMEC monolayer is correlated with penetration 
into the brain, we used C. neoformans traversal of HBMEC monolayer as a relevant 
biological assay to screen a chemical library for discovery of targets affecting C. 
neoformans traversal of the blood-brain barrier. Our chemical screen identified 
montelukast as an inhibitor of C. neoformans traversal of HBMEC monolayer, yet 
montelukast did not affect the growth of C. neoformans strains B-3501A and H99 and 
also did not affect the HBMEC viability, as assessed by live/dead stain (Molecular 
probes) (Stins et al., 2001).   Montelukast is a selective antagonist of cysteinyl 
leukotriene type 1 receptor (CysLT1) and inhibits cysteinyl leukotriene (CysLT) binding 
to CysLT1 (Peters-Golden and Henderson, 2007).  Since host CysLTs are formed via LT 
biosynthetic pathways involving cytosolic phospholipase A2α (cPLA2α) and 5-
lipoxygenase (5-LO), we hypothesize that host cPLA2α and 5-LO contribute to C. 
neoformans penetration of the blood-brain barrier.                                                                                                                                                                                                       
 
We showed that C. neoformans strains exploit host cPLA2α for their traversal of HBMEC 
monolayer, as shown by the time-dependent cPLA2α phosphorylation in response to C. 
neoformans strains B-3501A and H99 (Fig. 1A) and the ability of arachidonoyl 
trifluoromethylketone (AACOCF3, cPLA2α inhibitor) at 20 µM to significantly inhibit C. 
neoformans traversal of HBMEC monolayer (Fig. 1B). AACOCF3 at 20 µM was 
efficient in preventing cPLA2α phosphorylation in response to C. neoformans strains H99 
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(serotype A) and B-3501A (serotype D), but did not affect the growth of C. neoformans 
strains (Fig 1. C & D) or the integrity of the HBMEC monolayer, as assessed by live/dead 
staining (Molecular probes).  
 
We next examined whether pharmacologic inhibition and gene deletion of cPLA2α 
affects C. neoformans penetration into the brain in BALB/c mice. Each animal received 1 
x 105 colony forming units (CFUs) of C. neoformans strain B-3501A via the tail vein. 24 
hours later, blood specimens were obtained for determination of CFUs, and the animals 
perfused with sterile Ringer’s solution until the perfused solution became colorless.  The 
brains, spleens, kidneys and lungs were removed, weighed, homogenized and cultured for 
determinations of CFUs, as described previously (Chang et al., 2004; Maruvada et al., 
2012). C. neoformans strain B-3501A was completely cleared from the blood at 24 hours 
after intravenous injection and no viable yeasts were recovered from the blood. The 
CFUs in the brains were, therefore, most likely to represent the yeast cells that had 
penetrated into and survived in the brain.  
 
For pharmacological inhibition, AACOCF3 (4 mM in 50 μl PBS, a dose which inhibits 
cPLA2α activity in mice, Kalyvas et al., 2004) was administered intravenously 30 mins 
before C. neoformans injection, and this resulted in significantly decreased penetration of 
C. neoformans into the brain of BALB/c mice (Fig. 1E). In contrast, AACOCF3 did not 
affect C. neoformans penetration into the spleen, kidney and lung, as shown by similar 
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numbers of CFUs recovered from the animals receiving AACOCF3 or vehicle control 
(Fig. 1E).  
 
The effect of gene deletion of host cPLA2α in C. neoformans penetration into the brain 
was assessed in cPLA2α-/- mice compared to their littermate control cPLA2α+/+ mice 
(Sapirstein et al., 2005; Zhu et al, 2010). The yeast counts recovered from the brains 
(CFUs/gm) of cPLA2α-/- mice were significantly less than those of cPLA2α+/+ animals 
(Fig. 1F), while the yeast counts from the kidneys did not differ between cPLA2α-/- and 
cPLA2α+/+ mice. These findings support that host cPLA2α contributes to C. neoformans 
penetration into the brain in vivo. 
 
cPLA2α mediates arachidonic acid release from membrane phospholipids (Ghosh et al., 
2006), and  we examined whether exogenous arachidonic acid affects C. neoformans 
penetration into the brain of cPLA2α-/- mice. Intravenous administration of arachidonic 
acid (1.2 μg/mouse in 50 μl PBS, a dose which restores cPLA2α-dependent vascular 
responses in cPLA2α-/- mice, Ichinose et al., 2002; Zhu et al, 2010) 30 min before C. 
neoformans injection significantly enhanced C. neoformans penetration into the brain to 
the level observed in the wild type mice, while arachidonic acid failed to enhance C. 
neoformans penetration into the kidney (Fig. 1F). The enhancement of C. neoformans 
penetration into the brain by exogenous arachidonic acid in cPLA2α-/- mice was not 
This article is protected by copyright. All rights reserved.
 10 
accompanied by any changes in the blood-brain barrier permeability, as shown by a lack 
of significantly increased extravasation of intravenously administered Evans blue dye 
into the brain of infected animals receiving arachidonic acid compared to those without 
arachidonic acid administration. These findings are consistent with those of our previous 
studies, where C. neoformans penetration of the blood-brain barrier was not accompanied 
by any changes in the blood-brain barrier integrity (Chang et al., 2004). These in vitro 
and in vivo findings using pharmacological inhibition and gene deletion demonstrate that 
C. neoformans exploits host cPLA2α for traversal of the blood-brain barrier and 
penetration into the brain, while host cPLA2α does not affect C. neoformans penetration 
into non-brain organs.  
 
Leukotrienes (LTs) are synthesized from arachidonate by 5-lipoxygenase (5-LO) and 5-
LO activating protein (FLAP) (Peters-Golden and Henderson, 2007), and we next 
determined whether C. neoformans exploitation of host cPLA2α for penetration of the 
blood-brain barrier depends on 5-LO products of arachidonic acid. This issue was 
examined initially using zileuton (a selective inhibitor of 5-LO) and MK886 (an inhibitor 
of FLAP) for assessing their effect on C. neoformans traversal of HBMEC monolayer. 
Zileuton exhibited a dose-dependent inhibition of C. neoformans strains H99 and B-
3501A traversal of HBMEC, and MK886 at 50 µM inhibited strain H99 traversal of 
HBMEC (Fig. 2 A). Zileuton at 400 µM and MK886 at 50 µM did not affect the growth 
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of C. neoformans strains and also did not affect the integrity of HBMEC monolayer, as 
assessed by transendothelial electrical resistance (TEER) before and after traversal 
assays. The inhibition of HBMEC traversal by pharmacological inhibition of 5-LO and 
FLAP indicate that endogenous LT biosynthesis via 5-LO and FLAP is likely to play an 
important role in C. neoformans penetration of the blood-brain barrier. 
 
The role of 5-LO in C. neoformans penetration into the brain was examined using 5-LO-/- 
mice as compared to their strain-matched wild type mice (Serezani et al., 2005; Zhu et al., 
2010).  In these animal studies, C. neoformans strain H99 was administered via 
intravenous inoculation as described above, as well as via intratracheal inoculation to 
mimic the natural route of infection (acquisition via inhalation). The intravenous 
inoculation model measures the ability of C. neoformans to penetrate into the brain from 
systemic dissemination, while the intratracheal inoculation model measures the ability of 
extrapulmonary dissemination to the brain from the lungs, and both models have been 
used for assessing transcellular and Trojan-horse penetrations of the blood-brain barrier 
(Chang et al., 2004; Charlier et al., 2005; Chretien et al., 2002; Dromer et al., 2011; 
Neuville et al., 2002; Olszewski et al., 2004; Shi et al., 2010).  C. neoformans strain H99 
penetration into the brain following intravenous as well as intratracheal inoculations was 
significantly less in 5-LO-/- mice than in their wild type animals, as shown by 
significantly less yeast counts recovered from the brains of 5-LO -/- mice compared to 
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those of their wild type animals (Fig. 2, B & C). In contrast, the yeast counts recovered 
from the non-brain sites (e.g., spleen, kidney and lung) were similar between 5-LO-/- and 
wild type mice (Fig. 2, B &C). These findings demonstrate that C. neoformans exploits 
host 5-LO for penetration into the brain following intravenous and intratracheal 
administrations. 
 
Arachidonic acid is metabolized to LTB4 or cysteinyl leukotrienes (LTC4, LTD4 and 
LTE4) and these terminal LTs exhibit their biological actions via interaction with their 
respective G-protein coupled receptors, BLT1 and CysLT1 (Murphy et al., 2007; Peters-
Golden et al., 2007). The role of individual classes of LTs in C. neoformans penetration 
of the blood-brain barrier was next determined by examining the effects of the CysLT1 
antagonist (montelukast) and the BLT1 antagonist (CP105696) (Peters-Golden and 
Henderson, 2007) in cryptococcal traversal of the HBMEC monolayer. Pretreatment of 
HBMEC with montelukast significantly inhibited C. neoformans traversal in a dose-
dependent manner (Fig. 3, A & B), while CP105696 did not exhibit any inhibition (Fig. 
3C).  Montelukast at 50 µM did not affect the growth of C. neoformans strains and also 
did not affect the integrity of HBMEC monolayer, as assessed by TEER before and after 
traversal assays.  
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We next examined the effect of montelukast in C. neoformans penetration into the brain 
following intravenous inoculation. Administration of montelukast (1.6 mM in 100 μl 
PBS, a dose which exhibits CysLT1 antagonist activity in mice, Genovese et al., 2008) 
intravenously 15 mins before and 6 hours after C. neoformans injection significantly 
decreased C. neoformans penetration of the brain of BALB/c mice, but did not affect C. 
neoformans penetration into the spleen, kidney and lung (Fig. 3D).  These in vitro and in 
vivo findings with montelukast demonstrate for the first time that cysteinyl LTs 
contribute to C. neoformans penetration of the blood-brain barrier.  
 
CysLT1 antagonists have been developed for allergic airway disease and shown to be 
safe and well tolerated in clinical trials (Barnes et al., 1997; Capra et al., 2007; 
Montuschi et al., 2007).  Since CysLT1 antagonist (montelukast) was effective in 
preventing C. neoformans penetration of the blood-brain barrier, we next examined its 
efficacy in the treatment of C. neoformans CNS infection, alone and in combination with 
anti-fungal drug (fluconazole). The animals received C. neoformans via intratracheal 
inoculation, and then montelukast via intraperitonal administration, followed by daily 
administration of montelukast and fluconazole, alone or in combination, for 6 and 13 
days to mimic a likely application of these drugs for therapy of C. neoformans CNS 
infection. As expected, administration of fluconazole was effective in significantly 
inhibiting C. neoformans CFUs recovered from the brain compared to vehicle control 
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(Fig. 3,E &F).  The combination of montelukast and fluconazole, however, was 
significantly more effective than individual drugs alone in reducing C. neoformans CFUs 
recovered from the brain (Fig. 3, E & F).  
 
In addition, our immunofluorescence studies revealed that the expression of CysLT1 was 
evident in the brain capillaries of animals with C. neoformans penetration into the brain 
following intratracheal inoculation, while CysLT1 expression was not discernible in the 
brain capillaries of uninfected animals (Fig 4), suggesting that the CysLT1 expression in 
the brain capillaries is likely to be up-regulated with C. neoformans infection of the brain.  
 
Taken together, these findings suggest that counteracting a host factor involved in C. 
neoformans penetration of the blood-brain barrier (e.g., cysteinyl LTs) is beneficial in 
prevention and therapy of C. neoformans CNS infection, and also suggest that a 
combination of montelukast and fluconazole may represent an attractive  preemptive 
therapeutic regimen for asymptomatic CRAG+ persons with CD4<100/µl.  
 
It has been documented that eicosanoids can be produced not only by the host, but also 
by Cryptococcus phospholipase (Noverr et al., 2003; Noverr et al., 2001). We next 
examined whether prevention of C. neoformans penetration into the brain by the cPLA2α 
inhibitor and the CysLT1 antagonist was the result of their inhibitory effects on cysteinyl 
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LTs arising from arachidonate liberated by Cryptococcus or host phospholipase. This 
issue was examined by using the phospholipase B1 (plb1) mutant derived from C. 
neoformans strain H99 compared to its reconstituted strain along with wild type strain 
H99 (Noverr et al., 2003). As shown previously (Maruvada et al, 2012), the penetration 
of the plb1 mutant across the HBMEC monolayer was significantly decreased compared 
to that of the reconstituted strain and strain H99 (Fig 5A). AACOCF3 and montelukast 
were effective in significant inhibition of HBMEC traversal by the plb1 mutant, the 
reconstituted and wild type strains (Fig 5A). More importantly, the penetration of the 
plb1 mutant into the brain was significantly defective in cPLA2α-/- mice compared to wild 
type mice (Fig. 5B). In contrast, the yeast counts recovered from non-brain sites (kidney, 
spleen and lung) did not differ between cPLA2α-/- and wild type mice. We also showed 
that montelukast significantly inhibited the plb1 mutant’s penetration into the brain 
compared to vehicle control (Fig. 5C). Our findings with pharmacological inhibition of 
cPLA2α and CysLT1 as well as genetic deletion of cPLA2α are, therefore, likely to stem 
from their effect on host cPLA2α and CysLT1, not on fungal plb1, supporting that host 
cPLA2α and cysteinyl LTs contribute to C. neoformans traversal of HBMEC and 
penetration into the brain, independent of Cryptococcus phospholipase. These findings 
are also consistent with those of pharmacological inhibition studies (Fig 3 D, E & F), 
where C. neoformans penetration into the brain was prevented by administration of 
montelukast alone and in combination with fluconazole, indicating that host-derived, 
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rather than cryptococcal-derived, eicosanoid production is responsible for C. neoformans 
penetration of the blood-brain barrier. In addition, we showed that C. gattii strains 
exhibited the ability to traverse the HBMEC monolayer and their traversal frequency (1.3 
% to 2.4 %) was similar to that of C. neoformans. Of interest, C. gattii traversal was 
inhibited by AACOCF3 and montelukast (Fig 5D).  Taken together, the above findings 
demonstrate that host cPLA2α, 5-LO and cysteinyl LTs are exploited by C. neoformas 
var. neoformans (strain 3501A), C. neofromans var. grubii (strain H99) as well as C. 
gattii strains for penetration of the blood-brain barrier.  
 
Protein kinase C (PKC) is a family of at least 10 serine/threonine kinases that transduce 
multiple signals in the regulation of a variety of cellular functions, which include 
cytoskeleton rearrangements (Hryciw et al., 2005; Larsson et al., 2006). We have 
previously shown that C. neoformans exploits host cell cytoskeleton rearrangements for 
penetration of HBMEC monolayer, as documented by microvilli formation at the entry 
sites of HBMEC (Chang et al., 2004). We, therefore, hypothesized that C. neoformans 
exploits PKCα for traversal of HBMEC monolayer. The role of  PKCα in C. neoformans 
traversal of HBMEC monolayer was shown by our demonstrations that PKCα activation 
occurs in response to C. neoformans in a time-dependent manner in HBMEC (Fig. 6A), 
and that C. neoformans traversal was significantly decreased in HBMEC expressing 
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dominant-negative PKCα compared to the control vector-transfected HBMEC (Fig. 6, B 
& C).  
 
More importantly, PKCα activation in response to C. neoformans was inhibited by 
cPLA2α inhibitor (AACOCF3) and CysLT1 antagonist (montelukast), but not by BLT1 
antagonist (CP105696) (Fig. 6A). These findings indicate that host cPLA2α, 5-LO and 
cysteinyl LTs, but not LTB4, contribute to C. neoformans traversal of HBMEC 
monolayer, most likely via PKCα activation. This concept was further supported by our 
demonstration that exogenous cysteinyl LT (LTD4, 1 µM) significantly enhanced C. 
neoformans traversal of control vector-transfected HBMEC compared to vehicle control 
(0.5% ethanol), while it failed to exhibit such an enhancement in HBMEC expressing 
dominant-negative PKCα (Fig. 6, B & C). In addition, PKCα activation was shown to 
occur in response to LTD4, but not to LTB4, in HBMEC (Fig 6 D). Taken together, these 
findings demonstrate for the first time that PKCα is downstream of cPLA2α, 5-LO and 
cysteinyl LTs in C. neoformans penetration of the blood-brain barrier.  
 
cPLA2α has been shown to be involved in the development of arthritis, bone resorption 
and pulmonary fibrosis (Hegen et al., 2003; Miyaura et al., 2003; Nagase et al., 2002), 
while LTs have been involved in respiratory diseases, allergic diseases and 
cardiovascular diseases (Evans et al., 2008; Funk et al., 2005; Montuschi et al., 2007; 
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Peters-Golden and Henderson, 2007), but the roles of cPLA2α, 5-LO and LTs in C. 
neoformans penetration of the blood-brain barrier have not been explored. Our findings 
reported here demonstrate for the first time that (a) C. neoformans exploits host cPLA2α 
and 5-LO for the generation of cysteinyl LTs responsible for penetration of the blood-
brain barrier in vitro and in vivo, (b) the actions of cysteinyl LTs occur via CysLT1 and 
PKCα, and (c) the contribution of host cPLA2α and CysLT1 to C. neoformans penetration 
of the blood-brain barrier was independent of cryptococcal plb1. Our findings also 
demonstrate that inhibition of host molecules exploited by C. neoformans and C. gattii 
for penetration of the blood-brain barrier, as shown here with cPLA2α inhibitor and 
CysLT1 antagonist, is likely to provide a novel approach for prevention of C. neoformans 
and C. gattii penetration into the brain, the essential step required for development of 
meningoencephalitis. We also show that the CysLT1 antagonist (montelukast) in 
combination with anti-fungal drug (fluconazole) was significantly more effective than 
single agents alone in therapy of C. neoformans CNS infection. These findings suggest 
that pharmacologic inhibition of host factors involved in C. neoformans penetration of 
the blood-brain barrier is a useful adjunct to anti-fungal drugs in prevention and therapy 
of C. neoformans meningoencephalitis.  
 
Experimental procedures 
 
Reagents. 
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Arachidonic acid (AA) was purchased from Cayman Chemical Company (Ann Arbor, 
MI). Evans Blue was purchased from Sigma (St Louis, NO). Arachidonyltrifluoromethyl 
ketone (AACOCF3; cPLA2 inhibitor) was purchased from Biomol Laboratories. 
(Plymouth Meeting, PA). Leukotriene D4 (LTD4), Leukotriene B4 (LTB4), and 
montelukast (cysteinyl-leukotriene type 1 receptor antagonist) were purchased from 
Cayman Chemical Company (Ann Arbor, MI). CP105696 (LTB4 receptor antagonist) 
was a gift from Pfizer. cPLA2, phospho-cPLA2α and phospho-PKCα antibodies were 
purchased from Cell Signaling Technologies (Danvers, MA), and PKC antibodies, 
PECAM-1 antibodies, and cysteinyl-leukotriene type 1 receptor (CysLT1) antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA)  
 
Mice.  
 
cPLA2α-/- and littermate control cPLA2α+/+, either male or female, between 10~13w and 
18~26g, that had been backcrossed on the BALB/C strain for >10 generations (Sapirstein 
et al., 2005; Zhu et al, 2010), and female 5-LO-/- (129-Alox5tm1Fun/J) and strain-matched 
wild-type mice (129SvEv), 9~12w and 18~26g (Serezani et al., 2005; Zhu et al, 2010), 
were used. All procedures and handling techniques were approved by The Johns Hopkins 
Animal Care and Use Committee and Fujian Medical University Animal Care and Use 
Committee, Fuzhou, China. 
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Yeast strains.   
 C. neoformans strains H99 and B-3501A represent encapsulated serotype A and D 
strains, respectively, that have been used for genomic sequencing (Loftus et al., 2003).  
plb1 isogenic strain of H99 was generated as previously described (Cox et al., 2001).  
GFP-tagged H99 (H99-GFP) was provided by Robin C. May, University of Birmingham, 
UK (Voelz et al., 2010). C. gattii strains were provided by S. Zhang, Johns Hopkins 
Hopsital Microbiology Laboratory. Yeast cells were grown aerobically at 37 °C in 1 % 
yeast extract, 2 % peptone and 2 % glucose (YPD) broth. Cells were harvested at early 
exponential phase, washed with PBS and resuspended in Hams-F12/M199 (1: 1, v/v), 5 
% fresh human serum (experimental medium). The numbers of Cryptococcus cells were 
determined by direct counting from a haemocytometer, which was verified by 
determinations of colony forming units (CFUs) on YPD agar after 2 days of incubation at 
30° C. 
 
Characterization and culture of HBMEC. 
HBMEC were isolated and characterized as described previously (Stins et al., 1997). 
Briefly, brain specimens were cut into small pieces and homogenized in DMEM 
containing 2 % FBS (DMEM-S) using a Dounce homogenizer with a loose fitting. The 
homogenate was centrifuged in 15 % dextran in DMEM-S for 10 min at 10 000 g. The 
pellet containing crude microvessels was further digested in a solution containing 1 
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mg/ml collagenase/dispase in DMEM-S for 1 h at 37 °C. Microvascular capillaries were 
isolated by adsorption to a column of glass beads (0.25–0.3 mm) and washing off from 
the beads. HBMEC were plated on rat tail collagen/fibronectin-coated dishes or glass 
coverslips and cultured in RPMI 1640-based medium with growth factors, 10 % heat-
inactivated FBS, 10 % NuSerum, 5 U heparin ml-1, 2 mM L-glutamine, 1 mM sodium 
pyruvate, non-essential amino acids, vitamins and 100 U penicillin and streptomycin ml-
1. Viability of HBMEC was assessed by examining morphology and by trypan blue 
exclusion. HBMEC were positive for factor VIII-Rag, took up fluorescently labeled 
acetylated low-density lipoprotein and expressed -glutamyl transpeptidase. HBMEC 
were maintained in RPMI-based medium, including 10 % FBS and 10 % NuSerum (BD 
Biosciences), at 37 °C in a humid atmosphere of 5 % CO2.  
 
Identification of montelukast affecting C. neoformans traversal of primary HBMEC 
monolayer.    
We used C. neoformans traversal of the primary HBMEC monolayer as a biologically 
relevant assay for screen of the Johns Hopkins Drug Library (JHDL) (Chong et al., 2006) 
for identification of targets affecting C. neoformans traversal of the blood-brain barrier, 
as follows. Primary HBMEC grown in 96-well Transwell inserts (with a pore size of 8 
µm) were incubated with the JHDL (at a final concentration of 10 µM) for 60 min at 
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room temperature, and then examined for C. neoformans traversal, as previously 
described (Chang et al., 2004; Maruvada et al., 2012). This screening assay included 
strain H99 in vehicle (DMSO)-treated HBMEC as a positive control for transcytosis, 
while the wells without HBMEC were used as control for any inhibitory effect of the 
drugs on growth of C. neoformans. Since this JHDL contains antifungal drugs, those 
wells exposed to antifungals were used as a positive control for determination of drugs 
that affect C. neoformans growth. The assay was highly reproducible, and the coefficient 
of correlation from at least two separate experiments was r = 0.98 (P<0.0001). From this 
screen, we identified montelukast, an antagonist of cysteinyl leukotriene type 1 receptor 
(CysLT1) (Peters-Golden et al., 2007), inhibited C. neoformans traversal of HBMEC, 
without affecting HBMEC integrity, as assessed by live/dead stain (Molecular Probes) 
and C. neoformans growth. CysLT1 has not been previously appreciated for its 
involvement in C. neoformans penetration of the blood-brain barrier.  
 
Infection of HBMEC with adenovirus. 
HBMEC (~70% confluency) were infected (at MOI of 50) with dialyzed adenovirus of 
Ad5CA dominant negative-PKC-α and vector control, as described previously 
(Gorshkova et al., 2008) 
 
Traversal of C. neoformans across the HBMEC monolayer. 
HBMEC were cultured on Transwell polycarbonate tissue-culture inserts with a pore 
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diameter of 8 µm (Corning Costar) for 5 days (Chang et al., 2004). On the morning of the 
assay, HBMEC monolayer was washed with experimental medium and 107 C. 
neoformans cells were added to the upper chamber.  At 9 h of incubation at 37 °C, 
sample was taken from the lower chamber and plated for determinations of CFUs. 
Colonies were counted after 2 days of incubation at 30° C. The integrity of the HBMEC 
monolayer was assessed by measurements of the transendothelial electrical resistance 
(TEER) before and after assays.  
 
 
Experimental hematogenous C. neoformans CNS infection in mice 
Mice were anesthetized with pentobarbital sodium given subcutaneously at 50 mg/kg.  
Montelukast 5 mg/kg in 100µl PBS was injected through tail vein 15 min before and 6h 
after tail vein injection of C. neoformans (1×105 cells in 100 µl PBS). Control mice 
received 3.3% ethanol in 100 µl PBS. 24h after C. neoformans injection, mouse chest 
was cut open, and blood from right ventricle was collected and plated for bacterial counts 
(CFUs). Then mouse was perfused with a mammalian Ringer's solution by transcardiac 
perfusion through a 23-gauge needle inserted into the left ventricle of the heart under the 
perfusion pressure of about 100 mmHg. The perfusate exited through a cut in the right 
atrium. The composition of the mammalian Ringer solution was: (in mM) 132 NaCl, 4.6 
KCl, 2 CaCl2, 1.2 MgSO4, 5.5 glucose, 5.0 NaHCO3, and 20 HEPES and Na-HEPES, 
containing 10 mg/ml BSA; pH of the Ringer solution was maintained at 7.40–7.45 by 
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adjustment of the ratio of Na-HEPES to HEPES. Ringer solution used in this study has 
been shown not to change the microvessel permeability (Zhu et al, 2004). 30 min after 
perfusion of Ringer solution, mice were decapitated. The brains were removed, weighed 
and homogenized in 2ml RPMI followed by plating for brain Cryptococcus counts in 
YPD agar plates. Kidneys, lungs and spleens were also dissected out for determinations 
of bacterial counts (CFUs/gm). The brains were removed, weighed and homogenized in 
2ml RPMI followed by plating for brain Cryptococcus counts in YPD agar plates. 
 
Intratracheal inoculation 
Mice were anesthetized with pentobarbital sodium given subcutaneously at 50 mg/kg. 
A small incision was made in the skin over the trachea. A 30-gauge needle (Becton 
Dickinson, Franklin Lakes, NJ) was attached to a tuberculin syringe (Becton Dickinson). 
The needle was bent and inserted into the trachea, and (containing 105 CFU Cryptococcus) 
was delivered. For control (sham) group mice, a 30-µl PBS was delivered. The skin was 
sutured with a cyanoacrylate adhesive, and the mice recovered with no visible trauma 
(Noverr et al., 2003). 
   
 
Immunofluorescence 
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After 7 days of intratracheal inoculation with GFP-tagged C. neoformans (H99-GFP), 
mouse chest was cut open, and mouse was perfused with a mammalian Ringer's solution 
by transcardiac perfusion through a 23-gauge needle inserted into the left ventricle of the 
heart under the perfusion pressure of about 100 mmHg for 20 min. The brains were 
removed and put in liquid nitrogen. Serial cryosections (10 μm) were incubated overnight 
with a monoclonal rat anti-PECAM-1 primary antibody (Santa Cruz, CA) and a 
polyclonal rabbit anti-CysLT1primary antibody (Santa Cruz, CA).  Afterward, sections 
were incubated with Dylight 488 goat Anti-Rat IgG secondary antibody (EarthOx Life 
Sciences, Millbrae, CA) and Cy3 goat anti-Rabbit IgG secondary antibody (Beyotime 
Biotechnology, Shanghai, China). Slides were imaged through fluorescence microscopy 
with a Nikon Eclipse Ti-S and DS-Ri2 digital camera (Nikon) 
 
 
Immunoblotting and immunoprecipitation 
The lysates of HBMEC incubated with C. neoformans were prepared for Western 
blotting and immunoprecipitation as described previously (Reddy et al., 2000).  
 
Statistical Analysis 
 
Data are expressed as mean ± SEM. Differences of Cryptococcus counts in the brain, 
spleen, kidney and lung (CFUs/gm of organs) between different groups of mice were 
determined by Wilcoxon rank sum test or Student’s t test. Differences of Cryptococcus 
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traversal across HBMEC monolayer were determined by Student’s t test.  P<0.05 was 
considered significant.  
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Figures legends 
Figure 1. Host cPLA2α is involved in C. neoformans traversal of the HBMEC 
monolayer and penetration into the brain 
(A) Serine phosphorylation of cPLA2α occurs in response to C. neoformans strains B-
3501A and H99 in HBMEC in a time-dependent manner. The lysates of HBMEC 
incubated with C. neoformans were examined for phospho-cPLA2α and cPLA2α in 
Western blot analysis using specific antibodies.  
(B) AACOCF3 significantly inhibited penetration of C. neoformans strain B-3501A 
across the HBMEC monolayer. Penetration of B-3501A across the HBMEC monolayer 
was examined in Transwell filters (8 µm pore size). HBMECs were pretreated with 20 
µM AACOCF3 for 60 min and then 20 µM AACOCF3 solution were added to every 2 hr 
(0, 2, 4, 6, and 8 hr, respectively) after addition of 1×106 CFU of strain B-3501A to the 
upper chamber. Our previous studies revealed that traversal of C. neoformans across the 
HBMEC monolayer was evident over a 9 hr incubation period (Chang et al., 2004). At 9 
hr of incubation at 37 °C, sample was taken from the lower chamber and plated for 
determinations of CFUs. Colonies were counted after 2 days of incubation at 30° C. 
Transcytosis frequency (%) was determined by (total CFUs recovered from the lower 
chamber/total number of cryptococcal cells added to the upper chamber) x 100, and 
expressed as relative frequency compared to transcytosis frequency with vehicle control 
(0.125% ethanol). Transcytosis frequency of C. neoformans strain B-3501A across 
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HBMEC monolayer at 9 hr of incubation at 37 °C ranged between 1.4 and 8.9 %. Data 
shown are means ± SEM of triplicates. * P<0.05, unpaired t-test, compared to vehicle 
control. 
(C and D) AACOCF3, a cPLA2α inhibitor, and Montelukast, a CysLT1 receptor 
antagonist, show no significant effects on growth of C. neoformans strains H99 (C) or 
B3501A (D). 
C. neoformans strains H99 (C) or B3501A (D) were growing in Hams-F12/M199 (1: 1, 
v/v), 5 % heat inactivated fetal bovine serum (FBS) (experimental medium, XM) and 5 % 
fresh human serum (HS) at 37°C, 5% CO2 incubator. Cryptococcus counts were 
performed at 0, 9, and 24h incubation time. Data shown are mean ± SEM. Each 
experiment was performed in triplicate. 
 (E) AACOCF3 decreases C. neoformans B-3501A penetration into the brain of BALB/c 
mice (WT).  4 mM AACOCF3 in 50µl PBS was injected through tail vein 30 min before, 
3 hr and 6 hr after tail vein injection of  C. neoformans B-3501A (1×105 cells in 100µl 
PBS). Control mice were injected with 7% ethanol in100 µl PBS. Cryptococcus counts 
were determined 24 hr after injection of B-3501A. Data shown are mean ± SEM.  
*P<0.05, Student’s t-test between WT (n=5), and WT + AACOCF3 (n=5). 
(F) C. neoformans penetration into the brain of cPLA2α-/- and their wild type mice.  
Cryptococcus counts were determined 24 hr after injection of B-3501A (1×105 cells) in 
100 µl PBS through tail vein. 40 µM arachidonic acid (AA) in 100 µl PBS (1.2 
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µg/mouse) was injected through tail vein 30 min before C. neoformans injection. Data 
shown are mean ± SEM. * P<0.05, Student’s t-test between cPLA2α +/+ (n=5), cPLA2α-/- 
(n=5), and cPLA2α -/- + AA (n=3). 
 
Figure 2. 5-LO is involved in C. neoformans traversal across the HBMEC monolayer 
and penetration into the brain. 
(A) Zileuton (5-LO inhibitor) and MK886 (FLAP inhibitor) inhibited C. neoformans 
strain H99 traversal of the HBMEC monolayer in a dose-dependent manner. Data shown 
are means ± SEM of triplicates. * P<0.05, unpaired t-test, compared to vehicle control. 
(B) C. neoformans penetration into the brain following intravenous inoculation is 
significantly decreased in 5-LO-/- mice compared to their wild type animals. The yeast 
counts from the brain, kidney, and spleen were determined 24 hr after injection of H99 
(1×105 cells) in 100µl PBS through tail vein. Data shown are mean ± SEM. * P<0.05 by  
Student’s t-test between wild type (WT, n=4) and 5-LO-/- mice (KO, n=4). 
(C) C. neoformans penetration into the brain following intratracheal inoculation is 
significantly decreased in 5-LO-/-  mice compared to wild type mice. The yeast counts 
from the brain, spleen, and lung were determined 7d after intratracheal inoculation of 
H99 (1×105 cells). Data shown are mean ± SEM. # P<0.05 by Wilcoxon Rank Sum test 
between wild type (WT, n=6) and 5-LO-/- mice (KO, n=6). 
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Figure 3. Cysteinyl LTs are involved in C. neoformans traversal across the HBMEC 
monolayer and penetration into the brain. 
(A and B) Montelukast (CysLT1 antagonist), but (C) not CP105696 (BLT1 antagonist) 
inhibited traversal of C. neoformans strains H99 (A and C) and B-3501A (B) across the 
HBMEC monolayer. Transcytosis of H99 or B-3501A was examined in Transwell filters 
(8 µm pore size). HBMECs were pretreated with montelukast at indicated concentrations 
(1, 10, 50 µM) for 60 min and then montelukast solution were added every 4 hr (0, 4, and 
8 hr, respectively) after addition of 1×106 CFUs of strain H99 or B-3501A to the upper  
chamber. Data shown are mean ± SEM of triplicates. * P<0.05 by unpaired t-test, 
compared to vehicle control (0.1% ethanol). 
(D) Montelukast decreases C. neoformans H99 penetration into the brain of BALB/c 
mice. 1.6 mM montelukast in 100µl PBS was injected through tail vein 15 min before, 
and 6 hr after tail vein injection of H99 (1×105 cells in 100µl PBS). Control mice 
received 4% DMSO in100 µl PBS. The yeast counts were determined after 24 hr 
injection of H99 (n=6 for each group). Data shown are mean ± SEM. * P<0.05 by two-
tailed Wilcoxon Rank-Sum test. 
(E and F) Effects of montelukast and fluoconzole on C. neoformans penetration into the 
brain of BALB/c mice (E) 7 and (F) 14 d after intratracheal inoculation of H99. On the 
day of intratracheal inoculation of C. neoformans, montelukast (Mon) was given at dose 
of 5 mg/kg in 100 µl PBS via intraperitoneal (i.p.) injection 30 min before and 6 hr after 
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inoculation of H99, followed by 5 mg/kg i.p. daily for 6 and 13 d. After intratracheal 
inoculation of C. neoformans, fluconazole (Flu) was suspended in sterile water and was 
given at dose of 15 mg/kg twice daily in a volume about 100 µl by gavage for 6 and 13 d. 
Control animals received 3.3% DMSO i.p. and sterile water via oral gavage. The yeast 
counts from the brain were determined 7 and 14 d after intratracheal inoculation of H99 
(1×105 CFUs). Data represent mean ± SEM (n=10). * P<0.05 by Student’s t-test. 
 
Figure 4.  Immnofluorescence demonstration of CysLT1 in the mouse brain 
microvessels following intratracheal inoculation of GFP-tagged Cryptococcus 
neoformans (H99-GFP) 
 
CysLT1 expression was not evident in the brain microvessels of uninfected mice (Sham), 
while CysLT1 expression was demonstrated in the brain microvessels (shown with 
PECAM-1) of mice infected with GFP-tagged Cryptococcus neoformans (H99-GFP). A 
and D, CysLT1 expression; B and E, microvessels shown with PECAM-1; C and F, 
merge of CysLT1 and PECAM-1 staining.  Yellow arrows indicate H99-GFP, and white 
arrows indicate microvessels. Scale bar= 50 µm.  
 
Figure 5. Roles of cryptococccal Plb1 in C. neoformans penetration of the blood-
brain barrier. 
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(A). The plb1 mutant (ΔPLB1) was significantly defective in traversal of the 
HBMEC monolayer compared to its parent strain H99 and reconstituted strain 
(ΔPLB1 + R). AACOCF3, a cPLA2α inhibitor, and montelukast, the CysLT1 
antagonist, significantly inhibited the HBMEC traversal of the plb1 mutant, its 
parent strain and reconstituted strain.  Traversal of the HBMEC monolayer was 
examined in Transwell filters (8 µm pore size). HBMEC were pretreated with 20 µM  
AACOCF3 for 60 min and then 20 µM  AACOCF3 fresh solution were added to the 
transwell every 2 hr (0, 2, 4, 6, and 8 hr, respectively) or HBMECs were pretreated with 
50 µM montelukast for 60 min and then montelukast solution were added every 4 hr (0, 
4, and 8 hr, respectively) after addition of 1×106 CFUs of cryptococcal strains to the 
upper chamber. Data shown are means ± SEM of triplicates. * P<0.05, Student’s t-test 
compared to vehicle control (n=3). 
(B). The penetration of the plb1 mutant into the brain is significantly decreased in 
cPLA2α-/- mice compared to their wild type animals (WT). The yeast counts in the 
brain, kidney, spleen and lung were determined 24 hr after injection of the plb1 mutant 
(1×105 cells) in 100 µl PBS through the tail vein. Data shown are mean ± SEM. 
**P<0.001, Student’s t-test between WT and cPLA2 -/- mice (n=7). 
 (C). Montelukast (the CysLT1 antagonist) significantly decreases the penetration of 
the plb1 mutant into the brain of BALB/cJ mice. Montelukast 5 mg/kg in 100µl PBS 
was injected through tail vein 15 min before and 6 hr after tail vein injection of the plb1 
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mutant (1×105 cells in 100µl PBS). Control mice received 3.3% ethanol in 100µl PBS. 
The yeast counts were determined after 24 hr injection of the plb1 mutant (n=6). Data 
shown are mean ± SEM. * P<0.05, Wilcoxon Rank-Sum test. 
(D) C. gattii strains traversal of the HBMEC monolayer was inhibited by AACOCF3 and 
montelukast. Data shown are means ± SEM of triplicates. * P<0.05, Student’s t-test 
compared to vehicle control (n=3). 
 
 
Figure 6.  cPLA2α and cysteinyl LTs contribute to C. neoformans traversal of the 
HBMEC monolayer via PKCα 
 
(A) HBMEC incubated with C. neoformans strain H99 at 37o C for various times in the 
presence of inhibitors/antagonists or vehicle control were immunoprecipitated with PKCα 
antibody, and then assessed for phospho-PKC by Western blotting with phospho-PKC 
antibody. The HBMEC lysates were examined for the total amounts of PKC.  
(B and C) Effect of LTD4 on penetration of C. neoformans strain H99 (B) or B-3501A 
(C) across monolayer of HBMEC transfected with dominant-negative PKCα construct. 
Subconfluent HBMEC in transwell insert were infected with adenovirus Ad5CA 
dominant negative-PKC-α (DN) or vector control (Vec) at MOI of 50. HBMEC were 
pretreated with 1 µM LTD4 for 30 min followed by transcytosis assays. 0.5% ethanol 
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was used as vehicle control (Veh). Data shown are mean ± SEM. Each experiment was 
performed in triplicate.  *P <0.05; **P <0.01, Student’s t test. 
(D) LTD4 is involved in PKCα activation in HBMEC.  HBMEC incubated with LTD4 (1 
µM) or LTB4 (1 µM) at 37o C for various times (min) were immunoprecipitated with 
PKCα antibody, and then assessed for phospho-PKC by Western blotting with phospho-
PKC antibody. The HBMEC lysates were examined for the total amounts of PKC. 
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